Quantitative antibody test
AssigneeQuanterix Corporation
InventorsAndrew Ball, Lei Chang, Syrena Fernandes, Joe Johnson, Jeremy Lambert, Dawn Mattoon, Tatiana Plavina, David Wilson
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.
Claims21
A method for quantitatively detecting an antibody of a human to severe acute respiratory syndrome coronavirus 2 (BARS-Coir-2), which method comprises:
- a) contacting a sample from a human with SARS-CoV-2 S (spike) polypeptide, or a fragment thereof, to allow binding between an antibody to said SARS-CoV-2 S polypeptide, or a fragment thereof, if present in said sample, and said SARS-CoV-2 S polypeptide, or a fragment thereof;
- b) assessing a detectable signal due to binding between said antibody and said SARS-CoV-2 S polypeptide, or a fragment thereof;
- and
- c) comparing said detectable signal to a calibration data set generated using a calibrator antibody that specifically binds to said SARS-CoV-2 S polypeptide, or a fragment thereof, at multiple concentrations or levels to assess amount, concentration or level of said antibody in said sample, and
- wherein said calibrator antibody is a chimeric antibody, or a fragment thereof, that comprises a human constant region and a variable region component or a variable region of a non-human species, and
- wherein said calibration data set is generated using said calibrator antibody, or a fragment thereof, at concentrations or levels ranging from about 0.001 ng/mL to about 10,000 ng/mL.
Dependencies are inferred from the claim text.